Edgewise Therapeutics, Inc. (EWTX) Latest Company News

Oct 8, 2026, 12:00 UTC
Edgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%.
Source:
- prnewswire.com
Sep 22, 2026, 11:00 UTC
Edgewise Therapeutics unveiled the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain and improved cardiac relaxation while preserving systolic function in preclinical models.
Source:
- prnewswire.com
Aug 6, 2026, 00:00 UTC
Edgewise Therapeutics reported a net loss of $57.3 million for Q2 2026, with R&D expenses of $47.5 million and G&A expenses of $14.4 million.
Jul 13, 2026, 12:30 UTC
Edgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion.
Source:
Jun 16, 2026, 17:40 UTC
Edgewise Therapeutics released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial for a heart drug.
Source:
- benzinga.com
Jun 5, 2026, 03:37 UTC
Edgewise Therapeutics sold its muscular dystrophy program to Servier for $2.65 billion, receiving $1.55 billion upfront.
Source:
- seekingalpha.com
Jun 2, 2026, 16:15 UTC
Edgewise Therapeutics agreed to divest its neuromuscular business to Servier for $2.65 billion.
Source:
- zacks.com
Jun 1, 2026, 00:00 UTC
Edgewise Therapeutics agreed to sell its neuromuscular program including the sevasemten compound to Servier Pharmaceuticals LLC and Les Laboratoires Servier for $1.55 billion upfront plus potential milestones.
Source:

EWTX

Edgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%.

Edgewise Therapeutics unveiled the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain and improved cardiac relaxation while preserving systolic function in preclinical models.

Edgewise Therapeutics reported a net loss of $57.3 million for Q2 2026, with R&D expenses of $47.5 million and G&A expenses of $14.4 million.

Edgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion.

Edgewise Therapeutics released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial for a heart drug.

Edgewise Therapeutics sold its muscular dystrophy program to Servier for $2.65 billion, receiving $1.55 billion upfront.

Edgewise Therapeutics agreed to divest its neuromuscular business to Servier for $2.65 billion.

Edgewise Therapeutics agreed to sell its neuromuscular program including the sevasemten compound to Servier Pharmaceuticals LLC and Les Laboratoires Servier for $1.55 billion upfront plus potential milestones.